SCHEMBL14715327

SCHEMBL14715327

CN(C)CCNC(=O)C(NC(=O)c1ccc(-c2ccc(OCCO)cc2)cc1)C(=O)NO

nearest known ligand 0.52

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.50
HRH3 Q9Y5N1 2/20 0.47
PPARG P37231 1/20 0.43
UTS2R Q9UKP6 4/20 0.41
ESR1 P03372 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
ANPEP P15144 1/20 0.40
MCHR1 Q99705 1/20 0.40
ALOX5 P09917 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14714987 0.91 HRH3 (0.45) ALDH1A1HRH3PPARGANPEPMCHR1
SCHEMBL14714981 0.89 ANPEP (0.49) HRH3PPARGANPEP
SCHEMBL14714895 0.88 PPARG (0.46) HRH3PPARGANPEP
SCHEMBL14714497 0.88 PPARG (0.51) HRH3PPARGANPEP
SCHEMBL14714713 0.87 USP2 (0.46) HRH3PPARGANPEP
SCHEMBL14715049 0.87 PPARG (0.51) HRH3PPARGANPEP
SCHEMBL14715425 0.86 PPARG (0.50) HRH3PPARGANPEP
SCHEMBL14714574 0.85 PPARG (0.46) ALDH1A1HRH3PPARGANPEPMCHR1
SCHEMBL14714691 0.85 PPARG (0.43) HRH3PPARGANPEP
SCHEMBL14714845 0.85 HRH3 (0.45) HRH3PPARGANPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2562155-B1 HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO LTD (JP) 2019-06-05 EP disclosed
US-9499477-B2 Hydroxamic acid derivative TOYAMA CHEMICAL CO., LTD. (JP) 2016-11-22 US disclosed
US-9499477-B2 Hydroxamic acid derivative TOYAMA CHEMICAL CO., LTD. (JP) 2016-11-22 US disclosed
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 US disclosed
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 US disclosed
EP-2562155-A1 NOVEL HYDROXAMIC ACID DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-02-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE LCT, AGXT, HDAC9 ALDH1A1 2205/4885HRH3 1334/4885PPARG 972/4885
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE LCT, AGXT, HDAC9 ALDH1A1 2205/4885HRH3 1334/4885PPARG 972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.